Given the positive phase II data for Vir Biotechnology's products and the bullish sentiment from analysts reflected in their ratings and price targets...
Read
More
Given the positive phase II data for Vir Biotechnology's products and the bullish sentiment from analysts reflected in their ratings and price targets, I believe VIR has significant upward potential in the near term, making it an attractive buy for those looking to capitalize on its growth.